Arkolith/Insider Trading/AMLX/Form 4

Frates James M

Chief Financial OfficerAmylyx Pharmaceuticals, Inc. (AMLX) · full profile →Form 4 · filed Jan 8, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$37K
Net Open-Market Flow
-$37K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 6, 2026Sell(S)3K$11.11$37K177K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-007669) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML